Rheumatoid arthritis, insulin resistance, and diabetes

Joint Bone Spine

Volumn 84, Issue 4, 2017, Pages 411-416

  Nicolau, Julia ^a   Lequerré, Thierry ^b   Bacquet, Hélène ^c   Vittecoq, Olivier ^b  

^a HÔPITAL CHARLES NICOLLE   (France)

^b INSERM   (France)

^c Department of Intensive Care   (France)

Author keywords

Diabetes; Glucocorticoids; IL 1 ; IL 6; Insulin resistance; Rheumatoid arthritis; TNF

Indexed keywords

GLUCOCORTICOID; HYDROXYCHLOROQUINE; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA ANTAGONIST; INTERLEUKIN 6; INTERLEUKIN 6 ANTAGONIST; METHOTREXATE; PROTEIN INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; GLUCOSE; TUMOR NECROSIS FACTOR;

DIABETES MELLITUS; DISEASE ASSOCIATION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SHORT SURVEY; CARDIOVASCULAR DISEASE; COMORBIDITY; GENETICS; IMMUNOLOGY; METABOLISM; RISK FACTOR;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; INSULIN RESISTANCE; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85006172790     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2016.09.001     Document Type: Short Survey

References (60)

1. Soubrier, M., Barber Chamoux, N., Tatar, Z., et al. Cardiovascular risk in rheumatoid arthritis. Joint Bone Spine 81 (2014), 298–302.
2. Sattar, N., McCarey, D.W., Capell, H., et al. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108 (2003), 2957–2963.
3. van Halm, V.P., Peters, M.J., Voskuyl, A.E., et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis 68 (2009), 1395–1400.
4. Crowson, C.S., Nicola, P.J., Kremers, H.M., et al. How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease?. Arthritis Rheum 52 (2005), 3039–3044.
5. del Rincón, I., Freeman, G.L., Haas, R.W., et al. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum 52 (2005), 3413–3423.
6. Popa, C., Netea, M.G., van Riel, P.L., et al. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res 48 (2007), 751–762.
7. Mottillo, S., Filion, K.B., Genest, J., et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 56 (2010), 1113–1132.
8. Chung, C.P., Oeser, A., Solus, J.F., et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 196 (2008), 756–763.
9. Mirjafari, H., Farragher, T.M., Verstappen, S.M., et al. Seropositivity is associated with insulin resistance in patients with early inflammatory polyarthritis: results from the Norfolk Arthritis Register (NOAR): an observational study. Arthritis Res Ther, 13, 2011, R159.
10. Giles, J.T., Danielides, S., Szklo, M., et al. Insulin resistance in rheumatoid arthritis: disease related indicators and associations with the presence and progression of subclinical atherosclerosis. Arthritis Rheumatol 67 (2015), 626–636.
11. Dessein, P.H., Joffe, B.I., Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 54 (2006), 2765–2775.
12. Shahin, D., Eltoraby, E., Mesbah, A., et al. Insulin resistance in early untreated rheumatoid arthritis patients. Clin Biochem 43 (2010), 661–665.
13. Chung, C.P., Oeser, A., Solus, J.F., et al. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum 58 (2008), 2105–2112.
14. Bordon, Y., Immunometabolism: IL-6, the resistance fighter. Nat Rev Immunol 14 (2014), 282–283.
15. Hotamisligil, G.S., Shargill, N.S., Spiegelman, B.M., Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259 (1993), 87–91.
16. Hotamisligil, G.S., Peraldi, P., Budavari, A., et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271 (1996), 665–668.
17. Kanety, H., Feinstein, R., Papa, M., et al. Tumor necrosis factor alpha-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1. J Biol Chem 270 (1995), 23780–23784.
18. Catalán, V., Gómez-Ambrosi, J., Rodríguez, A., et al. Adipokines in the treatment of diabetes mellitus and obesity. Expert Opin Pharmacother 10 (2009), 239–254.
19. Ruan, H., Lodish, H.F., Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev 14 (2003), 447–455.
20. Després, J.P., Lamarche, B., Mauriège, P., et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334 (1996), 952–957.
21. Dubreuil, M., Rho, Y.H., Man, A., et al. Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study. Rheumatology (Oxford) 53 (2014), 346–352.
22. Liao, K.P., Gunnarsson, M., Källberg, H., et al. Specific association of type 1 diabetes mellitus with anti-cyclic citrullinated peptide-positive rheumatoid arthritis. Arthritis Rheum 60 (2009), 653–660.
23. Dieudé, P., Teixeira, V.H., Pierlot, C., et al. Testing for linkage and association with rheumatoid arthritis a PTPN22 promoter polymorphism reported to be associated and linked with type 1 diabetes in the Caucasian population. Ann Rheum Dis 67 (2008), 900–901.
24. Vaidya, B., Pearce, S.H., Charlton, S., et al. An association between the CTLA4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies. Rheumatology (Oxford) 41 (2002), 180–183.
25. Eyre, S., Hinks, A., Bowes, J., et al. Overlapping genetic susceptibility variants between three autoimmune disorders: rheumatoid arthritis, type 1 diabetes and coeliac disease. Arthritis Res Ther, 12, 2010, R175.
26. Chatzikyriakidou, A., Voulgari, P.V., Lambropoulos, A., et al. Validation of the TAGAP rs212389 polymorphism in rheumatoid arthritis susceptibility. Joint Bone Spine 80 (2013), 543–544.
27. Hollis-Moffatt, J.E., Chen-Xu, M., Topless, R., et al. Only one independent genetic association with rheumatoid arthritis within the KIAA1109-TENR-IL2-IL21 locus in Caucasian sample sets: confirmation of association of rs6822844 with rheumatoid arthritis at a genome-wide level of significance. Arthritis Res Ther, 12, 2010, R116.
28. Xu, W.D., Zhou, M., Peng, H., et al. Lack of association of IL-6 polymorphism with rheumatoid arthritis/type 1 diabetes: a meta-analysis. Joint Bone Spine 80 (2013), 477–481.
29. Pradhan, A.D., Manson, J.E., Rifai, N., et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286 (2001), 327–334.
30. Solomon, D.H., Karlson, E.W., Rimm, E.B., et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107 (2003), 1303–1307.
31. Han, C., Robinson, D.W. Jr., Hackett, M.V., et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33 (2006), 2167–2172.
32. del Rincón, I.D., Williams, K., Stern, M.P., et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44 (2001), 2737–2745.
33. Solomon, D.H., Love, T.J., Canning, C., et al. Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. Ann Rheum Dis 69 (2010), 2114–2117.
34. Lu, M.C., Yan, S.T., Yin, W.Y., et al. Risk of rheumatoid arthritis in patients with type 2 diabetes: a nationwide population-based case-control study. PLoS One, 9, 2014, e101528.
35. Su, C.C., Chen, I.E.C., Young, F.N., et al. Risk of diabetes in patients with rheumatoid arthritis: a 12-year retrospective cohort study. J Rheumatol 40 (2013), 1513–1518.
36. Simard, J.F., Mittleman, M.A., Prevalent rheumatoid arthritis and diabetes among NHANES III participants aged 60 and older. J Rheumatol 34 (2007), 469–473.
37. van Raalte, D.H., Brands, M., van der Zijl, N.J., et al. Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial. Diabetologia 54 (2011), 2103–2112.
38. Dessein, P.H., Joffe, B.I., Stanwix, A.E., et al. Glucocorticoids and insulin sensitivity in rheumatoid arthritis. J Rheumatol 31 (2004), 867–874.
39. Hoes, J.N., van der Goes, M.C., van Raalte, D.H., et al. Glucose tolerance, insulin sensitivity and β-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. Ann Rheum Dis 70 (2011), 1887–1894.
40. den Uyl, D., van Raalte, D.H., Nurmohamed, M.T., et al. Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction. Arthritis Rheum 64 (2012), 639–646.
41. Movahedi, M., Lunt, M., Ray, D., et al. Oral glucocorticoids and the risk of incident type ii diabetes mellitus in patients with rheumatoid arthritis, a retrospective cohort study. EULAR 2013. Ann Rheum Dis, 72, 2013, 239 [Abstract THU0222].
42. Peters, M.J., Symmons, D.P., McCarey, D., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69 (2010), 325–331.
43. Toms, T.E., Panoulas, V.F., John, H., et al. Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60 – more than just an anti-inflammatory effect? A cross sectional study. Arthritis Res Ther, 11, 2009, R110.
44. Solomon, D.H., Massarotti, E., Garg, R., et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 305 (2011), 2525–2531.
45. Rekedal, L.R., Massarotti, E., Garg, R., et al. Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases. Arthritis Rheum 62 (2010), 3569–3573.
46. Wasko, M.C., Hubert, H.B., Lingala, V.B., et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 298 (2007), 187–193.
47. Solomon, D.H., Garg, R., Lu, B., et al. Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial. Arthritis Care Res (Hoboken) 66 (2014), 1246–1251.
48. Gerstein, H.C., Thorpe, K.E., Taylor, D.W., et al. The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas: a randomized trial. Diabetes Res Clin Pract 55 (2002), 209–219.
49. Wasko, M.C., Kay, J., Hsia, E.C., et al. Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: risk reduction in a chronic inflammatory disease. Arthritis Care Res (Hoboken) 63 (2011), 512–521.
50. Antohe, J.L., Bili, A., Sartorius, J.A., et al. Diabetes mellitus risk in rheumatoid arthritis: reduced incidence with anti-tumor necrosis factor α therapy. Arthritis Care Res (Hoboken) 64 (2012), 215–221.
51. Stagakis, I., Bertsias, G., Karvounaris, S., et al. Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther, 14, 2012, R141.
52. Lillegraven, S., Greenberg, J.D., Reed, G.W., et al. Use of TNF inhibitors is associated with a reduced risk of diabetes in RA patients. EULAR 2013. Ann Rheum Dis, 72, 2013, 106 [Abstract OP0161].
53. Mandrup-Poulsen, T., Pickersgill, L., Donath, M.Y., Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol 6 (2010), 158–166.
54. Larsen, C.M., Faulenbach, M., Vaag, A., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356 (2007), 1517–1526.
55. Esser, N., Paquot, N., Scheen, A.J., Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Expert Opin Investig Drugs 25 (2014), 1–25.
56. 1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab. Ann Rheum Dis 70 (2011), 1164–1165.
57. Schultz, O., Oberhauser, F., Saech, J., et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One, 5, 2010, e14328.
58. Boyer, J.F., Gourraud, P.A., Cantagrel, A., et al. Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine 78 (2011), 179–183.
59. Burt, M.G., Willenberg, V.M., Petersons, C.J., et al. Screening for diabetes in patients with inflammatory rheumatological disease administered long-term prednisolone: a cross-sectional study. Rheumatology (Oxford) 51 (2012), 1112–1119.
60. Bartels, C.M., Saucier, J.M., Thorpe, C.T., et al. Monitoring diabetes in patients with and without rheumatoid arthritis: a Medicare study. Arthritis Res Ther, 14, 2012, R166.